Eli Lilly and Novo Nordisk both surpassed second-quarter estimates and raised their full-year outlooks, but investor reactions diverged sharply, highlighting a widening gap in Wall Street's confidence between the two obesity drug leaders [1]. Following Lilly's earnings release, its shares rose, while Novo Nordisk's stock declined after its own report, reflecting concerns about the Danish company's long-term growth prospects and pipeline clarity [1].
Eli Lilly reported a 48% year-over-year revenue increase, driven by strong demand for its diabetes treatment Mounjaro and obesity drug Zepbound. The company also raised its full-year revenue guidance, reinforcing investor confidence in its ability to maintain sales momentum despite facing lower prices in the U.S. market—a challenge also confronting Novo Nordisk [1]. According to Lilly's earnings presentation, the company held a 60.9% share of the U.S. obesity and diabetes drug market in Q2, compared to Novo Nordisk's 38.8% [1]. Bernstein analyst Courtney Breen stated, "The print reinforces our view that Lilly remains best positioned to capture the majority of global incretin market growth" [1].
Novo Nordisk also exceeded Wall Street expectations and increased its full-year outlook, attributing the performance to "increased expectations" for GLP-1 product sales. Analysts noted that Novo benefited from rebate adjustments and other temporary factors during the quarter, with sales of its diabetes drug Ozempic and overall obesity portfolio surpassing analyst estimates [1]. However, revenue from Novo's Wegovy pill fell slightly short of expectations, disappointing some investors and raising questions about its potential as a major growth driver [1]. BMO Capital Markets analyst Evan Seigerman commented, "While Novo raised guidance (as expected), the pipeline and path to sustainable growth remain less clear" [1]. Jefferies analyst Michael Leuchten added, "All in all this leaves many questions open for 2027" [1].
The market's reaction underscores a growing divide: while Lilly is seen as extending its lead and solidifying its position in the obesity drug market, Novo Nordisk faces skepticism about its ability to regain market share and deliver sustainable long-term growth [1].
CONCLUSION
Eli Lilly's strong Q2 performance and increased guidance have reinforced investor confidence, propelling its shares higher and widening its lead over Novo Nordisk in the obesity and diabetes drug market. In contrast, Novo Nordisk's results, though above expectations, left investors with concerns about future growth drivers and pipeline clarity. The market currently favors Lilly as the best-positioned company to capture future growth in the sector.